Skip to main content
OpenTrials
Recruiting

NCT Number: NCT04185272

Butyrophilins Role in Colon Cancer

quantification of BTNL molecules in colon cancer in order to determinate if their could be used as a prognostic marquer

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Colonic Cancer Colonic Diseases Colonic Neoplasms Colorectal Neoplasms Digestive System Diseases Digestive System Neoplasms Gastrointestinal Diseases Gastrointestinal Neoplasms Intestinal Diseases Intestinal Neoplasms Neoplasms Neoplasms by Site

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patient is older than 18 years old,
  • Signed participation consent,
  • Non-metastatic colon cancer immediately resectable or metastatic and liver synchronous for which it was decided a combined colic and liver surgery (metastatic patient at the outset) in multidisciplinary consultation meeting.
  • Performance Status (PS) 0 or 1
  • affiliated to the social security or beneficiary

Exclusion criteria

  • Rectal cancer, colon cancer recurrence
  • Emergency of colon cancer Surgery
  • History of inflammatory disease of the digestive tract (Crohn's disease or ulcerative colitis)
  • Patient who received neoadjuvant therapy other than chemotherapy
  • Patient treated with immune-suppressors or long-course corticosteroids <12 months
  • Pregnant women or likely to be pregnant (without effective contraception) or breastfeeding,
  • Person in urgent situation, person under legal protection measure, or unable to express his / her consent,
  • Impossibility of submitting to the medical examination of the test for geographical, social or psychological reasons

Treatment and study plan

analysis of BTN and BTNL status

Biological

analysis of BTN and BTNL expression in colon cancer and hepatic metastasis

Primary outcomes

  1. evaluation of BTNL3, BTNL8 and BTNL9 expression by transcriptomics and immunohistochemistry

    Time frame: 8 years

    healthy and cancerous colon ad metastasis (if applicable) will be analysed by

Study contacts

Contact information is provided by the study sponsor or research team.

Jihane PAKRADOUNI, PharmD,PhD

CONTACT

[email protected]

04 91 22 37 78

Laurie-Anne GOUTY, PhD

CONTACT

[email protected]

33491223778

Sponsors and collaborators

Lead sponsor

Institut Paoli-Calmettes

Other

Registry information

Official study title

Role of Butyrophilins in Colon Cancers Aggressiveness Evaluation

Important dates

Study start
2020
Primary completion
2027
Study completion
2028
First posted
Dec 4, 2019
Registry last updated
Jun 15, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.